ANCA-ASSOCIATED VASCULITIS (AAV)
Clinical trials for ANCA-ASSOCIATED VASCULITIS (AAV) explained in plain language.
Never miss a new study
Get alerted when new ANCA-ASSOCIATED VASCULITIS (AAV) trials appear
Sign up with your email to follow new studies for ANCA-ASSOCIATED VASCULITIS (AAV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New mRNA injection aims to tame autoimmune diseases
Disease control Recruiting nowThis early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a One-Time immune cell treatment tame severe vasculitis?
Disease control Recruiting nowThis Phase 2 trial tests a one-time infusion of rapcabtagene autoleucel, a CAR-T cell therapy made from a patient's own immune cells, against standard treatments for severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). About 126 adults aged 18-7…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug aims to tame rare blood vessel disease
Disease control Recruiting nowThis Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE3 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1, PHASE2 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immune reset: CAR-T therapy targets lupus, MS, and more
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Immune cell therapy shows promise for tough autoimmune cases
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: NA • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on lupus and scleroderma in new trial
Disease control Recruiting nowThis early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New blood test could end Trial-and-Error for arthritis drugs
Diagnosis Recruiting nowThis study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Bonn • Aim: Diagnosis
Last updated Jun 26, 2026 13:02 UTC
-
Full-Body scan may spot hidden inflammation and heart danger
Knowledge-focused Recruiting nowThis study is testing whether a special full-body PET scan can more accurately detect active ANCA-associated vasculitis (AAV) and predict long-term heart disease risk. Researchers will scan up to 120 participants (some with active AAV, some healthy) using three different tracers …
Matched conditions: ANCA-ASSOCIATED VASCULITIS (AAV)
Sponsor: University of Edinburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC